Log In
BCIQ
Print this Print this
 

CMV alphavaccine (AVX601)

  Manage Alerts
Collapse Summary General Information
Company AlphaVax Inc.
DescriptionVaccine containing three gene targets from cytomegalovirus (CMV)
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationCytomegalovirus (CMV)
Indication DetailsVaccinate against cytomegalovirus (CMV) infection
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$20.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/05/2009

Undisclosed

$20.0M

Undisclosed

Get a free BioCentury trial today